Your browser doesn't support javascript.
loading
Respuesta inmune mucosal inducida por proteoliposoma y cocleato derivados de N meningitidis serogrupo B
Campo, Judith del; Lastre, Miriam; Zayas, Caridad; Acevedo, Reinaldo; Gonzàlez, Elizabeth; Romeu, Belkis; Cuello, Maribel; Cabrera, Osmir; Balboa, Julio; Sarandi, Ali M; Pérez, Oliver.
Afiliación
  • Campo, Judith del; Finlay institute. Havana. Cuba
  • Lastre, Miriam; Finlay institute. Havana. Cuba
  • Zayas, Caridad; Finlay institute. Havana. Cuba
  • Acevedo, Reinaldo; Finlay institute. Havana. Cuba
  • Gonzàlez, Elizabeth; Finlay institute. Havana. Cuba
  • Romeu, Belkis; Finlay institute. Havana. Cuba
  • Cuello, Maribel; Finlay institute. Havana. Cuba
  • Cabrera, Osmir; Finlay institute. Havana. Cuba
  • Balboa, Julio; Finlay institute. Havana. Cuba
  • Sarandi, Ali M; Institute of Biomedicine University of Gothenburg. Alemania. Sweden
  • Pérez, Oliver; Finlay institute. Havana. Cuba
Vaccimonitor ; 18(2)mayo-ago. 2009. ilus, graf, tab
Artículo en Inglés | CUMED | ID: cum-43095
Biblioteca responsable: CU1.1
ABSTRACT
Mucosal vaccination offers attractive advantages to conventional systemic vaccination. Most pathogens enter or establish infection at mucosal surfaces. This represents an enormous challenge for vaccine development. Nevertheless, the availability of safe and effective adjuvants that function mucosally is the major limitation. Therefore, we investigated the impact of mucosal immunization with the Neisseria meningitidis B proteoliposome (AFPL1, Adjuvant Finlay Proteoliposome 1) and its-derived cochleate (Co, AFCo1). They contain multiple PAMPs as immunopotentiators and have delivery system ability as well as Th1 polarization activity. Groups of female mice were immunized by nasal, oral, intravaginal, or intramuscular routes with three doses with AFPL1/AFCo1 alone or containing ovalbumin or glycoprotein (g) D2 from Herpes Simplex Virus type 2 (HSV-2). High levels of specific IgG antibodies were detected in sera of mice vaccinated with either route. However, specific IgA antibodies were produced in saliva and vaginal wash only following mucosal delivering. The polarization to a Th1 pattern was confirmed by testing the induction of IgG2a/IgG2c antibody, positive delayed-type hypersensitivity reactions, and gIFN production. Additionally, AFCo1gD2 showed practically no vaginal HSV-2 replication and 100 percent protection against lethal vaginal HSV-2 challenge. In conclusion, the results support the use of AFCo1 as potent Th1 adjuvant for mucosal vaccines, particularly for nasal route(AU)
Asunto(s)


Texto completo: Disponible Colección: Bases de datos nacionales / Cuba Contexto en salud: Agenda de Salud Sostenible para las Américas Problema de salud: Objetivo 5: Medicamentos, vacunas y tecnologías sanitarias Base de datos: CUMED Asunto principal: Vacunas Meningococicas Idioma: Inglés Revista: Vaccimonitor Año: 2009 Tipo del documento: Artículo Institución/País de afiliación: Finlay institute/Cuba / Institute of Biomedicine University of Gothenburg/Sweden

Texto completo: Disponible Colección: Bases de datos nacionales / Cuba Contexto en salud: Agenda de Salud Sostenible para las Américas Problema de salud: Objetivo 5: Medicamentos, vacunas y tecnologías sanitarias Base de datos: CUMED Asunto principal: Vacunas Meningococicas Idioma: Inglés Revista: Vaccimonitor Año: 2009 Tipo del documento: Artículo Institución/País de afiliación: Finlay institute/Cuba / Institute of Biomedicine University of Gothenburg/Sweden
...